SEC Company Response from Zosano Pharma Corp (CIK 0001587221) — Apr 14, 2020
Zosano Pharma Corp (CIK 0001587221)
Date: April 14, 2020 · CIK: 0001587221 · Accession: 0001193125-20-107390
AI Filing Summary & Sentiment
File numbers found in text: 333-237187
Letter
Zosano Pharma Corporation
34790 Ardentech Court
Fremont, CA 94555
April 14, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Re: Zosano Pharma Corporation
Registration Statement on Form S-3 (Registration No. 333-237187)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the U.S. Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Zosano Pharma Corporation (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on April 16, 2020, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Richard Kim at (650) 470-4980.
Thank you for your assistance in this matter.
Very truly yours,
Zosano Pharma Corporation
Show Raw Text
CORRESP 1 filename1.htm CORRESP Zosano Pharma Corporation 34790 Ardentech Court Fremont, CA 94555 April 14, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Re: Zosano Pharma Corporation Registration Statement on Form S-3 (Registration No. 333-237187) Ladies and Gentlemen: In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the U.S. Securities and Exchange Commission (the “Commission”) of the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) of Zosano Pharma Corporation (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on April 16, 2020, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Richard Kim at (650) 470-4980. Thank you for your assistance in this matter. Very truly yours, Zosano Pharma Corporation By: /s/ Steven Lo Steven Lo Chief Executive Officer and President [Signature Page to Zosano Pharma Corporation Acceleration Letter]